AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.92−0.05 (-0.84%)
Close on Nov 17, 2026Market cap $148.00KP/E –Yield –
AgomAb Therapeutics cash
Cash and short-term investments held at the end of each period.
AgomAb Therapeutics's cash was €86.42M at Dec 31, 2025. For fiscal 2025 it was €86.42M, down 49.6% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €86.42M | -49.6% |
| FY2024 | Dec 31, 2024 | €171.46M | +40.1% |
| FY2023 | Dec 31, 2023 | €122.40M | +342.4% |
| FY2022 | Dec 31, 2022 | €27.67M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | €86.42M | – |
| Q4 FY2024 | Dec 31, 2024 | €171.46M | – |
| Q4 FY2023 | Dec 31, 2023 | €122.40M | – |
| Q4 FY2022 | Dec 31, 2022 | €27.67M | – |
See a number that looks wrong?